ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Kyungho Kim, Jing Li, Andrew Barazia, Alan Tseng, Seock Won Youn, Giovanni Abbadessa, Yi Yu, Brian Schwartz, Robert K. Andrews, Victor R. Gordeuk, Jaehyung Cho

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease'. Together they form a unique fingerprint.

Medicine & Life Sciences